Compare

ProPhase Labs, Inc. vs China Pharma Holdings, Inc. vs Ensysce Biosciences, Inc. vs Cerenome, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearProPhase Labs, Inc.
PRPH
China Pharma Holdings, Inc.
CPHI
Ensysce Biosciences, Inc.
ENSC
Cerenome, Inc.
CNSY
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$4.34M$4.14M$5.07M$5.21M
Revenue growth (YoY)-35.8%-8.5%-2.8%-10.5%
Gross margin31.9%-3.2%n/an/a
Operating margin-415.4%-78.2%-202.1%-293.5%
Net margin-339.3%-76.9%-200.8%-429.4%
Net income-$14.74M-$3.19M-$10.18M-$22.39M
EPS (Diluted)-$1.74-$0.74-$3.98-$0.29
Operating cash flow-$8.34M$148.3K-$7.81M-$20.77M
Free cash flow-$8.34M$88.9K-$7.93M-$20.84M
Cash & equivalents$90.0K$345.1K$4.31M$4.26M
Total assets$59.87M$31.00M$7.45M$16.32M
Total liabilities$56.36M$8.26M$4.57M$12.33M
Shareholders' equity$3.51M$22.74M$3.21M$4.00M
Return on year-end equity-420.3%-14.0%-316.6%-560.2%
Shares outstanding8.97M15.52M4.57M138.68M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearProPhase Labs, Inc.China Pharma Holdings, Inc.Ensysce Biosciences, Inc.Cerenome, Inc.
Latest$4.34M
Ended 2025-12-31
$4.14M
Ended 2025-12-31
$5.07M
Ended 2025-12-31
$5.21M
Ended 2025-12-31
1 year earlier$6.77M
Ended 2024-12-31
$4.53M
Ended 2024-12-31
$5.21M
Ended 2024-12-31
$5.82M
Ended 2024-12-31
2 years earlier$34.98M
Ended 2023-12-31
$7.01M
Ended 2023-12-31
$2.23M
Ended 2023-12-31
$4.91M
Ended 2023-12-31
3 years earlier$122.65M
Ended 2022-12-31
$8.10M
Ended 2022-12-31
$2.52M
Ended 2022-12-31
n/a
4 years earlier$79.04M
Ended 2021-12-31
$9.64M
Ended 2021-12-31
$3.53M
Ended 2021-12-31
n/a